Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P.
Ratziu V, et al. Among authors: abdelmalek m.
J Hepatol. 2023 Mar;78(3):479-492. doi: 10.1016/j.jhep.2022.10.023. Epub 2022 Nov 9.
J Hepatol. 2023.
PMID: 36334688
Free article.
Clinical Trial.